Literature DB >> 12126034

Managing benign prostatic hyperplasia.

Pamela Dull1, Robert W Reagan, Robert R Bahnson.   

Abstract

Medical and surgical options for the treatment of benign prostatic hyperplasia have expanded in recent years. Saw palmetto, the most widely used complementary medication, is less effective than standard medical therapy but has fewer side effects. Although non-selective alpha blockers provide rapid relief of symptoms and are relatively inexpensive, they can cause dizziness and orthostatic hypotension. These effects occur less often with tamsulosin, a more selective alpha blocker. Finasteride, a 5alpha-reductase inhibitor, slowly reduces prostatic volume but is not as effective as alpha blockers, especially in men with a smaller prostate. Dutasteride, a new 5alpha-reductase inhibitor, has recently been labeled for the treatment of benign prostatic hyperplasia. Surgery may be appropriate initial treatment in patients with severe symptoms who are not at high risk for complications. Surgery may also be indicated in patients who have failed medical therapy or have recurrent infection, hematuria, or renal insufficiency. Transurethral resection of the prostate is effective in most patients, but it carries some risk of sexual dysfunction, incontinence, and bleeding. Surgical procedures that use thermal microwave or laser energy to reduce hyperplastic prostate tissue have recently become available. In general, the newer procedures are less expensive than transurethral resection of the prostate and have fewer complications; however, the need for retreatment is somewhat greater with these less invasive techniques.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126034

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  7 in total

1.  Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats.

Authors:  Chetan Nandecha; Alok Nahata; Vinod Kumar Dixit
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

Review 2.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

3.  Androgen deprivation induces rapid involution and recovery of human prostate vasculature.

Authors:  Alejandro Godoy; Viviana P Montecinos; Danny R Gray; Paula Sotomayor; Jeffrey M Yau; R Robert Vethanayagam; Swaroop Singh; James L Mohler; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-10       Impact factor: 4.310

4.  Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: a single-blinded, randomized controlled trial.

Authors:  Jung-Sheng Yu; Kun-Hung Shen; Wen-Chi Chen; Jiann-Shyan Her; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-13       Impact factor: 2.629

5.  Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2005-06-30

6.  Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy.

Authors:  Mohammad Sajid Ali; Mohammad Sarfaraz Alam; Nawazish Alam; Masoom Raza Siddiqui
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

7.  A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.

Authors:  Emeka I Udeh; Chimaobi G Ofoha; David A Adewole; Ikenna I Nnabugwu
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.